Susan Lee's questions to SELLAS Life Sciences Group (SLS) leadership • Q3 2016
Question
Susan Lee from Maxim Group, on behalf of Jason McCarthy, asked for an update on the clinical development path for the GALE-301/302 programs and inquired about upcoming catalysts for the ongoing investigator-sponsored NeuVax studies.
Answer
President & CEO Mark Schwartz stated that for GALE-301/302, the company is still aggregating data from the Phase I/II trials to determine the optimal path forward. For NeuVax, he highlighted that enrollment for the Phase IIb combination trial with trastuzumab is expected to complete in Q1 2017, with an interim efficacy analysis in Q1 2018. He also noted that discussions with Dr. Reddy's for the gastric cancer trial are continuing. SVP of IR & Corporate Communications Remy Bernarda added that the DCIS trial is anticipated to initiate by the end of the year.